Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Citi Favors HENGRUI PHARMA w/ Shanghai's Promotion of Commercial Health Insurance High-Quality Development
Recommend 42 Positive 52 Negative 37 |
||||
|
||||
|
Recently, the Shanghai Financial Regulatory Bureau, Shanghai Medical Insurance Bureau, and other departments have jointly issued "Several Measures to Promote High-Quality Development of Commercial Health Insurance to Support Innovation in the Biopharmaceutical Industry", according to Citi's research report. The broker estimated that the Shanghai pilot program would gradually expand nationwide. Commercial insurance, as a new financial source for the healthcare system, should help drive the increased use of drugs, medical devices, diagnostics, and other medical procedures, with innovative products expected to particularly benefit, said the report. Within Citi's research scope, the main beneficiaries are believed to include HENGRUI PHARMA (01276.HK), HANSOH PHARMA (03692.HK), SINO BIOPHARM (01177.HK), INNOVENT BIO (01801.HK), and PA GOODDOCTOR (01833.HK). AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
